Risk of Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis and the Role of Prophylactic Salazosulfapyridine
International Journal of Rheumatic Diseases · 2025
DOI: 10.1111/1756-185x.70516 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Ryo Sato und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Pneumonia, Pneumocystis, Antirheumatic Agents, Sulfasalazine. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study aimed to assess the risk factors for Pneumocystis pneumonia (PCP) in patients with rheumatoid arthritis (RA) and investigate the potential of salazosulfapyridine (SASP) as a prophylactic agent.
Methods
The present study analyzed data from the Japanese Diagnosis Procedure Combination database, which provides comprehensive inpatient data (including diagnoses, procedures, and medications) covering a large portion of the population. We identified patients with RA who developed PCP among 14 190 patients diagnosed with RA at admission with a treatment history. Patients with RA who were receiving therapeutic doses of drugs for PCP were defined as having PCP. A nested case–control analysis was performed to compare patients with RA and PCP with age‐ and sex‐matched control patients with RA without PCP in a ratio of 1:20.
Results
The cohort comprised 132 patients with PCP and 2575 controls. The risk factors for PCP in RA were chronic obstructive pulmonary disease, methotrexate (MTX), biological/targeted synthetic DMARDs (b/tsDMARDs), and high‐dose glucocorticoids. SASP may have a protective effect against PCP, particularly in patients with RA treated with MTX and/or b/tsDMARDs.
Conclusion
The large sample size of the present study suggests that SASP may be associated with a reduced PCP risk in RA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan.
- Department of Advanced Medicine, Nagoya University Hospital, Aichi, Japan.
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan.
- Medical IT Center, Nagoya University Hospital, Aichi, Japan.
ORCID-Profile: Kenya Terabe, Koji Sakamoto, Junya Hasegawa, Mochihito Suzuki
Zitieren
APA
Sato, R., Terabe, K., Imaizumi, T., Sakamoto, K., Sato, K., Hasegawa, J., Sugiura, T., Ono, Y., Suzuki, M., Asai, S., & Imagama, S. (2025). Risk of Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis and the Role of Prophylactic Salazosulfapyridine. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70516
Vancouver
Sato R, Terabe K, Imaizumi T, Sakamoto K, Sato K, Hasegawa J, et al. Risk of Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis and the Role of Prophylactic Salazosulfapyridine. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70516
BibTeX
@article{Sato2025,
author = {Sato, Ryo and Terabe, Kenya and Imaizumi, Takahiro and Sakamoto, Koji and Sato, Kikue and Hasegawa, Junya and Sugiura, Takaya and Ono, Yusuke and Suzuki, Mochihito and Asai, Shuji and Imagama, Shiro},
title = {Risk of Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis and the Role of Prophylactic Salazosulfapyridine},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
doi = {10.1111/1756-185x.70516}
}
EUVIMED